A Closer Look: Roche’s Move On Danoprevir Shines Light On Innovation Strategy In China
This article was originally published in PharmAsia News
Executive Summary
Roche Pharmaceuticals Asia Pacific Head Luke Miels talks to PharmAsia News about the company’s recent deal with Ascletis, its thinking on China’s hepatitis C market and additional opportunities for out-licensing.
You may also be interested in...
Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
Will World's Largest HCV Population Have Access To Newest Treatments?
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.